# Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

> **NCT00722176** · PHASE2 · COMPLETED · sponsor: **BioLineRx, Ltd.** · enrollment: 220 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** BL-1020
- **DRUG:** BL-1020 10-30 mg
- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00722176
- **Lead sponsor:** BioLineRx, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-07
- **Final completion:** 2009-12
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2010-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00722176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00722176, "Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00722176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*